Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic ...

Alkermes plc ALKS announced that it has initiated the phase II Vibrance-3 study, evaluating the novel, investigational and ...

Idiopathic hypersomnia is a neurological sleep disorder characterised by excessive daytime sleepiness despite getting a full ...

Dr Leah Kaylor, a psychologist and sleep expert says: “Occasionally, more sleep may be required after emotionally intense ...

Secondary endpoints include change in Idiopathic Hypersomnia Severity Scale (IHSS) score and incidence of adverse events. The study is expected to enroll approximately 96 patients with IH across ...

There remains high unmet need for the idiopathic hypersomnia community, as evidenced by a recent survey conducted by the Sleep Consortium1 in which more than 90% of patients surveyed indicated ...

Alkermes (ALKS) announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to ...

NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Sleep latency is the term that describes the time it takes you to fall asleep. It’s thought that on average, we generally ...